Abstract
This review evaluates the current literature based on the impact of antibiotics on the intestinal microbiota and the critical role of intestinal bacteria in controlling infection and subsequent clinical disease caused by STEC and Salmonella, and the transmissibility of these important pathogens.A number of studies have indicated that antibiotic therapy could result in unexpected changes in the clinical picture of disease. This is observed, for example, in the case of infections associated with Shiga-toxin-producing Escherichia coli (STEC), when antibiotics used in treatment of the disease may increase the risk of hemolytic uremic syndrome (HUS) and thus fatal outcomes. In the case of such infections, treatment with antibiotics is usually discouraged. The use of antibiotics could cause also undesirable changes in the intestinal microbial flora and prolonged pathogen shedding, which is observed in the case of Salmonella infections. Inappropriate antibiotic therapy can result in Salmonella remaining in the host’s cells (intracellular) and thus resulting in further asymptomatic carriage and a further complication is the development of resistance.
Keywords: Escherichia coli, EHEC, STEC, HUS, Salmonella, antibiotics, side effect, microbiota, asymptomatic carriage.
Current Pharmaceutical Design
Title:Impact of Antibiotics on the Intestinal Microbiota and on the Treatment of Shiga-toxin-Producing Escherichia coli and Salmonella Infections
Volume: 20 Issue: 28
Author(s): Jolanta Szych, Tomasz Wolkowicz, Roberto La Ragione and Grzegorz Madajczak
Affiliation:
Keywords: Escherichia coli, EHEC, STEC, HUS, Salmonella, antibiotics, side effect, microbiota, asymptomatic carriage.
Abstract: This review evaluates the current literature based on the impact of antibiotics on the intestinal microbiota and the critical role of intestinal bacteria in controlling infection and subsequent clinical disease caused by STEC and Salmonella, and the transmissibility of these important pathogens.A number of studies have indicated that antibiotic therapy could result in unexpected changes in the clinical picture of disease. This is observed, for example, in the case of infections associated with Shiga-toxin-producing Escherichia coli (STEC), when antibiotics used in treatment of the disease may increase the risk of hemolytic uremic syndrome (HUS) and thus fatal outcomes. In the case of such infections, treatment with antibiotics is usually discouraged. The use of antibiotics could cause also undesirable changes in the intestinal microbial flora and prolonged pathogen shedding, which is observed in the case of Salmonella infections. Inappropriate antibiotic therapy can result in Salmonella remaining in the host’s cells (intracellular) and thus resulting in further asymptomatic carriage and a further complication is the development of resistance.
Export Options
About this article
Cite this article as:
Szych Jolanta, Wolkowicz Tomasz, Ragione La Roberto and Madajczak Grzegorz, Impact of Antibiotics on the Intestinal Microbiota and on the Treatment of Shiga-toxin-Producing Escherichia coli and Salmonella Infections, Current Pharmaceutical Design 2014; 20 (28) . https://dx.doi.org/10.2174/13816128113196660730
DOI https://dx.doi.org/10.2174/13816128113196660730 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Brain Signaling During Sepsis
Current Neuropharmacology B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) subject Index To Volume 2
Current Medicinal Chemistry - Central Nervous System Agents Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews The Patenting and Technological Trends in Candidiasis Treatment: A Systematic Review (2014-2018)
Current Topics in Medicinal Chemistry Association of Genetic Variation with Pneumonia
Current Respiratory Medicine Reviews Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research Perspectives on Tuberculosis Pathogenesis and Discovery of Anti- Tubercular Drugs
Current Medicinal Chemistry Effective Antiviral Medicinal Plants and Biological Compounds Against Central Nervous System Infections: A Mechanistic Review
Current Drug Discovery Technologies Nanomedicine in Therapeutic Intervention of Tuberculosis Meningitis
Current Nanoscience Treatment of CNS Malignancies with a Recombinant Oncolytic Poliovirus
Drug Design Reviews - Online (Discontinued) A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Small Neuroscience: The Nanostructure of the Central Nervous System and Emerging Nanotechnology Applications
Current Nanoscience Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets